Fulgent Genetics P/E Ratio

Fulgent Genetics (FLGT) currently reports a P/E ratio of -7.25. That is below the Healthcare sector average of 24.78. Use the charts on this page to explore Fulgent Genetics's P/E ratio history and peer comparisons.

Fulgent Genetics's P/E ratio of -7.25 is lower than the Healthcare sector average of 24.78. That is roughly 129.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Fulgent Genetics's market price to a fundamental measure such as earnings, sales, or book value. At -7.25, FLGT can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -7.25, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 24.78. From there, open related valuation or income-statement pages for Fulgent Genetics, and consider following FLGT for alerts when major investors trade the stock.

Fulgent Genetics is classified in the Healthcare sector. On P/E ratio, it currently shows -7.25 versus a sector average near 24.78. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FLGT with unrelated industries.